ProQR Therapeutics (PRQR) Share-based Compensation (2013 - 2026)

ProQR Therapeutics (PRQR) has reported Share-based Compensation for 14 consecutive years, with $1.6 million the latest figure, recorded in Q1 2026.

• Quarterly Share-based Compensation rose 88.39% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.3 million (up 82.54% YoY) and the FY2025 annual result came in at $4.6 million, up 57.78% from the prior year.
• Share-based Compensation advanced to $1.6 million in Q1 2026 per PRQR's latest filing, from $1.4 million in the prior quarter.
• Over the last five years, Share-based Compensation for PRQR reached as high as $1.6 million in Q1 2026 and fell as low as -$440388.3 in Q4 2022.
• A 5-year average of $934528.2 and a median of $870535.0 in 2023 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2022 — Share-based Compensation tumbled 121.73% — and 2023, when it soared 307.24%.
• Year by year, Share-based Compensation stood at -$440388.3 in 2022, then soared by 307.24% to $912639.3 in 2023, then retreated by 29.18% to $646358.0 in 2024, then surged by 116.55% to $1.4 million in 2025, then gained by 16.1% to $1.6 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $1.6 million, $1.4 million, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.